P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins

FASEB Journal

Volumn 21, Issue 13, 2007, Pages 3562-3572

  Hostettler, Nina ^a   Naggi, Annamaria ^b   Torri, Giangiacomo ^b   Ishai Michaeli, Riva ^c   Casu, Benito ^b   Vlodavsky, Israel ^c   Borsig, Lubor ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Heparin derivatives; LMWH; Selectin interactions; Thrombin generation

Indexed keywords

CELL ADHESION MOLECULE; HEPARAN SULFATE; HEPARANASE; HEPARIN DERIVATIVE; L SELECTIN; N ACETYL BETA GLUCOSAMINIDASE; PADGEM PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INVASION; CELL INTERACTION; CELL TYPE; COLON CARCINOMA; CONTROLLED STUDY; DEGRADATION; DRUG SELECTIVITY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LEUKOCYTE; MELANOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; TREATMENT RESPONSE; TUMOR MODEL;

ANIMALS; CELL LINE, TUMOR; FLOW CYTOMETRY; GLUCURONIDASE; HEPARIN; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; P-SELECTIN;

MUS;

EID: 35948980396     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-8450com     Document Type: Article

References (54)

1. Lazo-Langner, A., Goss, G. D., Spaans, J. N., and Rodger, M. A. (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J. Thromb. Haemost. 5, 729-737
2. Zacharski, L. R., Ornstein, D. L., and Mamourian, A. C. (2000) Low-molecular-weight heparin and cancer. Semin. Thromb. Hemost. 26. Suppl. 1, 69-77
3. Smorenburg, S. M., Hettiarachchi, R. J., Vink, R., and Buller, H. R. (1999) The effects of unfractionated heparin on survival in patients with malignancy - a systematic review. Thromb. Haemost. 82, 1600-1604
4. Cosgrove, R. H., Zacharski, L. R., Racine, E., and Andersen, J. C. (2002) Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin. Thromb. Hemost. 28, 79-88
5. Kakkar, A. K., Levine, M. N., Kadziola, Z., Lemoine, N. R., Low, V., Patel, H. K., Rustin, G., Thomas, M., Quigley, M., and Williamson, R. C. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22, 1944-1948
6. Lee, A. Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., and Levine, M. N. (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 23, 2123-2129
7. Lee, A. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., and Gent, M. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146-153
8. Klerk, C. P., Smorenburg, S. M., Otten, H. M., Lensing, A. W., Prins, M. H., Piovella, F., Prandoni, P., Bos, M. M., Richel, D. J., van Tienhoven, G., and Buller, H. R. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 23, 2130-2135
9. Altinbas, M., Coskun, H. S., Er, O., Ozkan, M., Eser, B., Unal, A., Cetin, M., and Soyuer, S. (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2, 1266-1271
10. Rickles, F. R. (2006) Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol. Haemost. Thromb. 35, 103-110
11. Lever, R., and Page, C. P. (2002) Novel drug development opportunities for heparin. Nat. Rev. Drug. Discov. 1, 140-148
12. Hettiarachchi, R. J., Smorenburg, S. M., Ginsberg, J., Levine, M., Prins, M. H., and Buller, H. R. (1999) Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb. Haemost. 82, 947-952
13. Mousa, S. A. (2002) Anticoagulants in thrombosis and cancer: the missing link. Semin. Thromb. Hemost. 28, 45-52
14. Jayson, G. C., and Gallagher, J. T. (1997) Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br. J. Cancer 75, 9-16
15. Mousa, S. A., and Mohamed, S. (2004) Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb. Haemost. 92, 627-633
16. Vlodavsky, I., Mohsen, M., Lider, O., Svahn, C. M., Ekre, H. P., Vigoda, M., Ishai-Michaeli, R., and Peretz, T. (1994) Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14, 290-302
17. Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., and Varki, A. (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. U. S. A. 98, 3352-3357
18. Varki, N. M., and Varki, A. (2002) Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost. 28, 53-66
19. Smorenburg, S. M., and Van Noorden, C. J. (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. 53, 93-105
20. Zacharski, L. R. (2002) Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett. 186, 1-9
21. Borsig, L., Wong, R., Hynes, R. O., Varki, N. M., and Varki, A. (2002) Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci. U. S. A. 99, 2193-2198
22. Ludwig, R. J., Boehme, B., Podda, M., Henschler, R., Jager, E., Tandi, C., Boehncke, W. H., Zollner, T. M., Kaufmann, R., and Gille, J. (2004) Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 64, 2743-2750
23. Kragh, M., Binderup, L., Vig Hjarnaa, P. J., Bramm, E., Johansen, K. B., and Frimundt Petersen, C. (2005) Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol. Rep. 14, 99-104
24. Stevenson, J. L., Choi, S. H., and Varki, A. (2005) Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res. 11, 7003-7011
25. Ono, K., Ishihara, M., Ishikawa, K., Ozeki, Y., Deguchi, H., Sato, M., Hashimoto, H., Saito, Y., Yura, H., Kurita, A., and Maehara, T. (2002) Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br. J. Cancer 86, 1803-1812
26. Yoshitomi, Y., Nakanishi, H., Kusano, Y., Munesue, S., Oguri, K., Tatematsu, M., Yamashina, I., and Okayama, M. (2004) Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 207, 165-174
27. Edovitsky, E., Elkin, M., Zcharia, E., Peretz, T., and Vlodavsky, I. (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J. Natl. Cancer Inst. 96, 1219-1230
28. Cohen, I., Pappo, O., Elkin, M., San, T., Bar-Shavit, R., Hazan, R., Peretz, T., Vlodavsky, I., and Abramovitch, R. (2006) Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int. J. Cancer 118, 1609-1617
29. Vlodavsky, I., Abboud-Jarrous, G., Elkin, M., Naggi, A., Casu, B., Sasisekharan, R., and Ilan, N. (2006) The impact of heparanase and heparin on cancer metastasis and angiogenesis. Pathophysiol. Haemost. Thromb. 35, 116-127
30. Ley, K. (2003) The role of selectins in inflammation and disease. Trends. Mol. Med. 9, 263-268
31. Lowe, J. B. (2003) Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr. Opin. Cell Biol. 15, 531-538
32. Laubli, H., Stevenson, J. L., Varki, A., Varki, N. M., and Borsig, L. (2006) L-selectin facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of tumor cell arrest. Cancer Res. 66, 1536-1542
33. Koenig, A., Norgard-Sumnicht, K., Linhardt, R., and Varki, A. (1998) Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Invest. 101, 877-889
34. Zacharski, L. R., and Ornstein, D. L. (1998) Heparin and cancer. Thromb. Haemost. 80, 10-23
35. Naggi, A., Casu, B., Perez, M., Torri, G., Cassinelli, G., Penco, S., Pisano, C., Giannini, G., Ishai-Michaeli, R., and Vlodavsky, I. (2005) Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J. Biol. Chem. 280, 12103-12113
36. Nagasawa, K., and Uchiyama, H. (1978) Preparation and properties of biologically active fluorescent heparins. Biochim. Biophys. Acta 544, 430-440
37. Singh, R., Pan, S., Mueske, C. S., Witt, T., Kleppe, L. S., Peterson, T. E., Slobodova, A., Chang, J. Y., Caplice, N. M., and Simari, R. D. (2001) Role for tissue factor pathway in murine model of vascular remodeling. Circ. Res. 89, 71-76
38. Bar-Ner, M., Kramer, M. D., Schirrmacher, V., Ishai-Michaeli, R., Fuks, Z., and Vlodavsky, I. (1985) Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells. Int. J. Cancer 35, 483-491
39. Lapierre, F., Holme, K., Lam, L., Tressler, R. J., Storm, N., Wee, J., Stack, R. J., Castellot, J., and Tyrrell, D. J. (1996) Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 6, 355-366
40. Gao, Y., Li, N., Fei, R., Chen, Z., Zheng, S., and Zeng, X. (2005) P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin. Mol. Cells 19, 350-355
41. Wang, L., Brown, J. R., Varki, A., and Esko, J. D. (2002) Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J. Clin. Invest. 110, 127-136
42. Tobu, M., Ma, Q., Iqbal, O., Schultz, C., Jeske, W., Hoppensteadt, D. A., and Fareed, J. (2005) Comparative tissue factor pathway inhibitor release potential of heparins. Clin. Appl. Thromb. Hemost. 11, 37-47
43. Valentin, S., Larnkjer, A., Ostergaard, P., Nielsen, J. I., and Nordfang, O. (1994) Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb. Res. 75, 173-183
44. Alban, S. (2001) Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin. Thromb. Hemost. 27, 503-511
45. Elkin, M., Ilan, N., Ishai-Michaeli, R., Friedmann, Y., Papo, O., Pecker, I., and Vlodavsky, I. (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J. 15, 1661-1663
46. Kim, Y. J., Borsig, L., Varki, N. M., and Varki, A. (1998) P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 95, 9325-9330
47. Mousa, S. A. (2004) Low-molecular-weight heparin in thrombosis and cancer. Semin. Thromb. Hemost. 30. Suppl. 1, 25-30
48. Ohyama, C., Tsuboi, S., and Fukuda, M. (1999) Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J. 18, 1516-1525
49. Mannori, G., Crottet, P., Cecconi, O., Hanasaki, K., Aruffo, A., Nelson, R. M., Varki, A., and Bevilacqua, M. P. (1995) Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res. 55, 4425-4431
50. Parish, C. R., Freeman, C., Brown, K. J., Francis, D. J., and Cowden, W. B. (1999) Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 59, 3433-3441
51. Honn, K. V., Tang, D. G., and Crissman, J. D. (1992) Platelets and cancer metastasis: a causal relationship? Cancer Metastasis. Rev. 11, 325-351
52. Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., Spector, L., and Pecker, I. (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5, 793-802
53. Hulett, M. D., Freeman, C., Hamdorf, B. J., Baker, R. T., Harris, M. J., and Parish, C. R. (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5, 803-809
54. Im, J. H., Fu, W., Wang, H., Bhatia, S. K., Hammer, D. A., Kowalska, M. A., and Muschel, R. J. (2004) Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 64, 8613-8619